Targeted proteomics improves cardiovascular risk prediction in secondary prevention

Abstract

Aims Current risk scores do not accurately identify patients at highest risk of recurrent atherosclerotic cardiovascular disease (ASCVD) in need of more intensive therapeutic interventions. Advances in high-throughput plasma proteomics, analysed with machine learning techniques, may offer new opportunities to further improve risk stratification in these patients. Methods and results Targeted plasma proteomics was performed in two secondary prevention cohorts: the Second Manifestations of ARTerial disease (SMART) cohort (n = 870) and the Athero-Express cohort (n = 700). The primary outcome was recurrent ASCVD (acute myocardial infarction, ischaemic stroke, and cardiovascular death). Machine learning techniques with extreme gradient boosting were used to construct a protein model in the derivation cohort (SMART), which was validated in the Athero-Express cohort and compared with a clinical risk model. Pathway analysis was performed to identify specific pathways in high and low C-reactive protein (CRP) patient subsets. The protein model outperformed the clinical model in both the derivation cohort [area under the curve (AUC): 0.810 vs. 0.750; P < 0.001] and validation cohort (AUC: 0.801 vs. 0.765; P < 0.001), provided significant net reclassification improvement (0.173 in validation cohort) and was well calibrated. In contrast to a clear interleukin-6 signal in high CRP patients, neutrophil-signalling-related proteins were associated with recurrent ASCVD in low CRP patients. Conclusion A proteome-based risk model is superior to a clinical risk model in predicting recurrent ASCVD events. Neutrophil-related pathways were found in low CRP patients, implying the presence of a residual inflammatory risk beyond traditional NLRP3 pathways. The observed net reclassification improvement illustrates the potential of proteomics when incorporated in a tailored therapeutic approach in secondary prevention patients. Key question Does targeted plasma proteomics improve cardiovascular risk prediction in secondary prevention patients? Are different pathways contributing to cardiovascular risk in high and low C-reactive protein (CRP) patients? Key finding Cardiovascular risk prediction with targeted plasma proteomics outperformed prediction with clinical risk factors resulting in major net reclassification improvement. Neutrophil-signalling-related proteins were associated with cardiovascular events in low CRP patients. Take-home message Routine implementation of a targeted protein panel in cardiovascular risk prediction holds promise to improve risk stratification in secondary prevention. The involvement of neutrophil-related pathways in low CRP patients indicates residual inflammatory risk beyond NLRP3.

From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators

“…Current proteomic technologies can be broadly characterised as mass spectrometry-based, antibody-based, or aptamer-based, but the broad dynamic range of proteins is often a hurdle for comprehensive and scalable characterisation of the proteome that is under active development [46]. Still, proteins have the advantage of being functionally closer to phenotypes and reflecting some environmental factors, such as smoking [47] or diet [48,49], making them well-suited for predicting disease risk [50][51][52], and yielding insights into mechanistic pathways [53,54]. In addition, proteins are translatable to a broad range of therapeutic modalities for drug discovery but such applications require the additional burden of establishing a causal role in disease.…”

Proteomics, dietary intake, and changes in cardiometabolic health within a behavioral weight‐loss intervention: A pilot study

“…The CVD III panel covers 92 proteins related to CVD and inflammation, providing normalized protein expression (NPX) data, with higher values indicating higher protein concentrations but not absolute quantifications. The 92 proteins are enriched in biological pathways such as angiogenesis, blood vessel morphogenesis, inflammatory response, and platelet activation and they have been associated with clinical indicators of cardiovascular risk in several studies [19][20][21]. For the completed array, the mean intra-assay coefficient of variation was 13% among all samples and assays.…”

Identification of thrombotic biomarkers in orthopedic surgery patients by plasma proteomics

“…Proteomic technology is an efficient tool for identifying potential biomarkers associated with pathological states [ 19 , 20 ]. With the rapid development of mass spectrometry (MS), proteomics can be used to accurately profile global proteomic alterations in various cells, tissues and body fluids.…”